Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report serves as a notification regarding a revision to the company's dividend payment schedule for 2014 and 2015.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is exclusively focused on corporate governance updates regarding dividend dates.
Material Changes
The primary material change is a revision to the Q3 2014 ex-dividend date. This adjustment was necessitated by the implementation of T+2 settlement in the UK effective October 6, 2014. All other previously published dividend dates remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the operational change in settlement cycles affecting the dividend calendar.
Investor Verification Points
- Verify the updated Q3 2014 ex-dividend date of November 6, 2014, against brokerage records.
- Confirm the impact of the UK T+2 settlement implementation on future dividend timing.
- Note that Q4 2013, Q1 2014, and Q2 2014 dividend dates remain as previously announced.